BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tsukuda S, Watashi K. Hepatitis B virus biology and life cycle. Antiviral Res. 2020;182:104925. [PMID: 32866519 DOI: 10.1016/j.antiviral.2020.104925] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
Number Citing Articles
1 Sabnis RW. Substituted Chromen-4-one Derivatives for Treating Hepatitis B Virus Infection. ACS Med Chem Lett 2021;12:322-3. [PMID: 33738053 DOI: 10.1021/acsmedchemlett.1c00076] [Reference Citation Analysis]
2 Bousali M, Papatheodoridis G, Paraskevis D, Karamitros T. Hepatitis B Virus DNA Integration, Chronic Infections and Hepatocellular Carcinoma. Microorganisms 2021;9:1787. [PMID: 34442866 DOI: 10.3390/microorganisms9081787] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Lai X, Chen W, Wu Y, Gao Y, Zhang Y, Xu X, Fu Y, Wang X, Yang Y, Zhang Y. Effect of mutations across reverse transcriptase region on HBV replication and progression of liver diseases in Chinese patients. J Clin Lab Anal 2022;:e24530. [PMID: 35657116 DOI: 10.1002/jcla.24530] [Reference Citation Analysis]
4 Saracco GM, Marzano A, Rizzetto M. Therapy of Chronic Viral Hepatitis: The Light at the End of the Tunnel? Biomedicines 2022;10:534. [DOI: 10.3390/biomedicines10030534] [Reference Citation Analysis]
5 Wang R, Xie Z. A Simple and Rapid Method for Quantitative Detection of Hepatitis B Virus Drug-resistant Mutations. J Clin Transl Hepatol 2021;9:139-40. [PMID: 34007793 DOI: 10.14218/JCTH.2021.00135] [Reference Citation Analysis]
6 Brown R, Goulder P, Matthews PC. Sexual Dimorphism in Chronic Hepatitis B Virus (HBV) Infection: Evidence to Inform Elimination Efforts. Wellcome Open Res 2022;7:32. [DOI: 10.12688/wellcomeopenres.17601.2] [Reference Citation Analysis]
7 Wei L, Ploss A. Mechanism of Hepatitis B Virus cccDNA Formation. Viruses 2021;13:1463. [PMID: 34452329 DOI: 10.3390/v13081463] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Kobayashi C, Watanabe Y, Oshima M, Hirose T, Yamasaki M, Iwamoto M, Iwatsuki M, Asami Y, Kuramochi K, Wakae K, Aizaki H, Muramatsu M, Sureau C, Sunazuka T, Watashi K. Fungal Secondary Metabolite Exophillic Acid Selectively Inhibits the Entry of Hepatitis B and D Viruses. Viruses 2022;14:764. [DOI: 10.3390/v14040764] [Reference Citation Analysis]
9 Kong F, Zhang F, Liu X, Qin S, Yang X, Kong D, Pan X, You H, Zheng K, Tang R. Calcium signaling in hepatitis B virus infection and its potential as a therapeutic target. Cell Commun Signal 2021;19:82. [PMID: 34362380 DOI: 10.1186/s12964-021-00762-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Posso-Osorio I, Tobón GJ, Cañas CA. Human endogenous retroviruses (HERV) and non-HERV viruses incorporated into the human genome and their role in the development of autoimmune diseases. J Transl Autoimmun 2021;4:100137. [PMID: 34917914 DOI: 10.1016/j.jtauto.2021.100137] [Reference Citation Analysis]
11 Kong F, Li Q, Zhang F, Li X, You H, Pan X, Zheng K, Tang R. Sirtuins as Potential Therapeutic Targets for Hepatitis B Virus Infection. Front Med (Lausanne) 2021;8:751516. [PMID: 34708060 DOI: 10.3389/fmed.2021.751516] [Reference Citation Analysis]
12 Patel N, Abulwerdi F, Fatehi F, Manfield I, Le Grice S, Schneekloth JS Jr, Twarock R, Stockley PG. Dysregulation of Hepatitis B Virus Nucleocapsid Assembly in vitro by RNA-binding Small Ligands. J Mol Biol 2022;:167557. [PMID: 35341740 DOI: 10.1016/j.jmb.2022.167557] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Luk KC, Gersch J, Harris BJ, Holzmayer V, Mbanya D, Sauleda S, Rodgers MA, Cloherty G. More DNA and RNA of HBV SP1 splice variants are detected in genotypes B and C at low viral replication. Sci Rep 2021;11:23838. [PMID: 34903774 DOI: 10.1038/s41598-021-03304-w] [Reference Citation Analysis]
14 Bianca C, Sidhartha E, Tiribelli C, El-Khobar KE, Sukowati CHC. Role of hepatitis B virus in development of hepatocellular carcinoma: Focus on covalently closed circular DNA . World J Hepatol 2022; 14(5): 866-884 [DOI: 10.4254/wjh.v14.i5.866] [Reference Citation Analysis]
15 Bartoli A, Gabrielli F, Tassi A, Cursaro C, Pinelli A, Andreone P. Treatments for HBV: A Glimpse into the Future. Viruses 2021;13:1767. [PMID: 34578347 DOI: 10.3390/v13091767] [Reference Citation Analysis]
16 Wang J, Du L, Tang H. Suppression of Interferon-α Treatment Response by Host Negative Factors in Hepatitis B Virus Infection. Front Med (Lausanne) 2021;8:784172. [PMID: 34901094 DOI: 10.3389/fmed.2021.784172] [Reference Citation Analysis]
17 Chuang Y, Tsai K, Ou JJ. Pathogenicity and virulence of Hepatitis B virus. Virulence 2022;13:258-96. [DOI: 10.1080/21505594.2022.2028483] [Reference Citation Analysis]
18 Virzì A, Gonzalez-Motos V, Tripon S, Baumert TF, Lupberger J. Profibrotic Signaling and HCC Risk during Chronic Viral Hepatitis: Biomarker Development. J Clin Med 2021;10:977. [PMID: 33801181 DOI: 10.3390/jcm10050977] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
19 Popa GL, Popa MI. Oxidative Stress in Chronic Hepatitis B—An Update. Microorganisms 2022;10:1265. [DOI: 10.3390/microorganisms10071265] [Reference Citation Analysis]
20 Brown R, Goulder P, Matthews PC. Sexual Dimorphism in Chronic Hepatitis B Virus (HBV) Infection: Evidence to Inform Elimination Efforts. Wellcome Open Res 2022;7:32. [DOI: 10.12688/wellcomeopenres.17601.1] [Reference Citation Analysis]
21 Brown R, Goulder P, Matthews PC. Sexual Dimorphism in Chronic Hepatitis B Virus (HBV) Infection: Evidence to Inform Elimination Efforts. Wellcome Open Res 2022;7:32. [DOI: 10.12688/wellcomeopenres.17601.3] [Reference Citation Analysis]
22 Wu D, Ding Q, Tao N, Tan M, Zhang Y, Li F, Zhou Y, Dong M, Cheng S, Ren F, Chen J, Ren J. SIRT2 Promotes HBV Transcription and Replication by Targeting Transcription Factor p53 to Increase the Activities of HBV Enhancers and Promoters. Front Microbiol 2022;13:836446. [DOI: 10.3389/fmicb.2022.836446] [Reference Citation Analysis]
23 Maepa MB, Bloom K, Ely A, Arbuthnot P. Hepatitis B virus: promising drug targets and therapeutic implications. Expert Opin Ther Targets 2021;25:451-66. [PMID: 33843412 DOI: 10.1080/14728222.2021.1915990] [Reference Citation Analysis]
24 Shah NJ, Aloysius MM, Sharma NR, Pallav K. Advances in treatment and prevention of hepatitis B. World J Gastrointest Pharmacol Ther 2021; 12(4): 56-78 [PMID: 34316384 DOI: 10.4292/wjgpt.v12.i4.56] [Reference Citation Analysis]
25 Elizalde MM, Tadey L, Mammana L, Quarleri JF, Campos RH, Flichman DM. Biological Characterization of Hepatitis B virus Genotypes: Their Role in Viral Replication and Antigen Expression. Front Microbiol 2021;12:758613. [PMID: 34803982 DOI: 10.3389/fmicb.2021.758613] [Reference Citation Analysis]
26 Yang L, Wang H, Yan H, Wang K, Wu S, Li Y. (-)-Lariciresinol Isolated from the Roots of Isatis indigotica Fortune ex Lindl. Inhibits Hepatitis B Virus by Regulating Viral Transcription. Molecules 2022;27:3223. [PMID: 35630700 DOI: 10.3390/molecules27103223] [Reference Citation Analysis]
27 Diogo Dias J, Sarica N, Neuveut C. Early Steps of Hepatitis B Life Cycle: From Capsid Nuclear Import to cccDNA Formation. Viruses 2021;13:757. [PMID: 33925977 DOI: 10.3390/v13050757] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Lau G, Yu ML, Wong G, Thompson A, Ghazinian H, Hou JL, Piratvisuth T, Jia JD, Mizokami M, Cheng G, Chen GF, Liu ZW, Baatarkhuu O, Cheng AL, Ng WL, Lau P, Mok T, Chang JM, Hamid S, Dokmeci AK, Gani RA, Payawal DA, Chow P, Park JW, Strasser SI, Mohamed R, Win KM, Tawesak T, Sarin SK, Omata M. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatol Int 2021;15:1031-48. [PMID: 34427860 DOI: 10.1007/s12072-021-10239-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
29 Kang B, Yi DY, Choe B. Translational Strategies to Eliminate Chronic Hepatitis B in Children: Prophylaxis and Management in East Asian Countries. Front Pediatr 2022;9:809838. [DOI: 10.3389/fped.2021.809838] [Reference Citation Analysis]
30 Tarn WY, Cheng Y, Ko SH, Huang LM. Antisense Oligonucleotide-Based Therapy of Viral Infections. Pharmaceutics 2021;13:2015. [PMID: 34959297 DOI: 10.3390/pharmaceutics13122015] [Reference Citation Analysis]
31 Wang SH, Yeh SH, Chen PJ. Unique Features of Hepatitis B Virus-Related Hepatocellular Carcinoma in Pathogenesis and Clinical Significance. Cancers (Basel) 2021;13:2454. [PMID: 34070067 DOI: 10.3390/cancers13102454] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
32 Tsai KN, Ou JJ. Hepatitis B virus e antigen and viral persistence. Curr Opin Virol 2021;51:158-63. [PMID: 34717215 DOI: 10.1016/j.coviro.2021.10.003] [Reference Citation Analysis]
33 Sandmann L, Cornberg M. Towards eradication of HBV: Treatment approaches and status of clinical trials. Curr Opin Pharmacol 2021;60:232-40. [PMID: 34474210 DOI: 10.1016/j.coph.2021.07.008] [Reference Citation Analysis]
34 Philips CA, Ahamed R, Abduljaleel JK, Rajesh S, Augustine P. Critical Updates on Chronic Hepatitis B Virus Infection in 2021. Cureus 2021;13:e19152. [PMID: 34733599 DOI: 10.7759/cureus.19152] [Reference Citation Analysis]
35 Shah NJ, Aloysius MM, Sharma NR, Pallav K. Advances in treatment and prevention of hepatitis B. WJGPT 2021;12:56-78. [DOI: 10.4292/wjg.v12.i4.56] [Reference Citation Analysis]
36 Sabnis RW. Novel Substituted 3,4-Dihydroquinazoline Derivatives for Treating Hepatitis B Virus Infection. ACS Med Chem Lett 2021;12:1065-6. [PMID: 34267871 DOI: 10.1021/acsmedchemlett.1c00296] [Reference Citation Analysis]
37 Hozáková L, Vokatá B, Ruml T, Ulbrich P. Targeting the Virus Capsid as a Tool to Fight RNA Viruses. Viruses 2022;14:174. [DOI: 10.3390/v14020174] [Reference Citation Analysis]
38 Prifti GM, Moianos D, Giannakopoulou E, Pardali V, Tavis JE, Zoidis G. Recent Advances in Hepatitis B Treatment. Pharmaceuticals (Basel) 2021;14:417. [PMID: 34062711 DOI: 10.3390/ph14050417] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Prieto C, Montecinos J, Jiménez G, Riquelme C, Garrido D, Hernández S, Loyola A, Villanueva RA. Phosphorylation of Phylogenetically Conserved Amino Acid Residues Confines HBx within Different Cell Compartments of Human Hepatocarcinoma Cells. Molecules 2021;26:1254. [PMID: 33652602 DOI: 10.3390/molecules26051254] [Reference Citation Analysis]
40 Yousaf T, Sun Y, Naz W, Liu Y, Xu J, Yuan S, Wu K, Wang M, Wang J, Guo M, Sun G. Multiomics Analysis of Endocytosis upon HBV Infection and Identification of SCAMP1 as a Novel Host Restriction Factor against HBV Replication. IJMS 2022;23:2211. [DOI: 10.3390/ijms23042211] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Martinez SS, Huang Y, Acuna L, Laverde E, Trujillo D, Barbieri MA, Tamargo J, Campa A, Baum MK. Role of Selenium in Viral Infections with a Major Focus on SARS-CoV-2. Int J Mol Sci 2021;23:280. [PMID: 35008706 DOI: 10.3390/ijms23010280] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
42 Dias JD, Sarica N, Cournac A, Koszul R, Neuveut C. Crosstalk between Hepatitis B Virus and the 3D Genome Structure. Viruses 2022;14:445. [PMID: 35216038 DOI: 10.3390/v14020445] [Reference Citation Analysis]
43 Laras A, Papatheodoridi M, Panopoulou E, Papatheodoridis GV, Hadziyannis SJ, Hadziyannis E. Serum hepatitis B virus RNA detectability, composition and clinical significance in patients with ab initio hepatitis B e antigen negative chronic hepatitis B. Virol J 2022;19. [DOI: 10.1186/s12985-022-01749-7] [Reference Citation Analysis]
44 Lasagna A, Zuccaro V, Sacchi P, Chiellino S, Bruno R, Pedrazzoli P. Risk of reactivation of occult hepatitis B during immunotherapy in cancer treatment: myth, reality or new horizons? Future Oncol 2021;17:1577-80. [PMID: 33590770 DOI: 10.2217/fon-2020-1196] [Reference Citation Analysis]
45 Zhang D, Zhang K, Protzer U, Zeng C. HBV Integration Induces Complex Interactions between Host and Viral Genomic Functions at the Insertion Site. J Clin Transl Hepatol 2021;9:399-408. [PMID: 34221926 DOI: 10.14218/JCTH.2021.00062] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Inoue J, Sato K, Ninomiya M, Masamune A. Envelope Proteins of Hepatitis B Virus: Molecular Biology and Involvement in Carcinogenesis. Viruses 2021;13:1124. [PMID: 34208172 DOI: 10.3390/v13061124] [Reference Citation Analysis]
47 Jeng LB, Li TC, Hsu SC, Teng CF. Association of Increased Programmed Death Ligand 1 Expression and Regulatory T Cells Infiltration with Higher Hepatocellular Carcinoma Recurrence in Patients with Hepatitis B Virus Pre-S2 Mutant after Curative Surgical Resection. Viruses 2022;14:1346. [PMID: 35746817 DOI: 10.3390/v14061346] [Reference Citation Analysis]
48 de la Fuente IF, Sawant SS, Tolentino MQ, Corrigan PM, Rouge JL. Viral Mimicry as a Design Template for Nucleic Acid Nanocarriers. Front Chem 2021;9:613209. [PMID: 33777893 DOI: 10.3389/fchem.2021.613209] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
49 Khan IW, Dad Ullah MU, Choudhry M, Ali MJ, Ali MA, Lam SLK, Shah PA, Kaur SP, Lau DTY. Novel Therapies of Hepatitis B and D. Microorganisms 2021;9:2607. [PMID: 34946209 DOI: 10.3390/microorganisms9122607] [Reference Citation Analysis]